129 related articles for article (PubMed ID: 27796539)
21. Pharmacokinetics and Safety of Cotadutide, a GLP-1 and Glucagon Receptor Dual Agonist, in Individuals with Renal Impairment: A Single-Dose, Phase I, Bridging Study.
Klein G; Petrone M; Yang Y; Hoang T; Hazlett S; Hansen L; Flor A
Clin Pharmacokinet; 2023 Jun; 62(6):881-890. PubMed ID: 37140727
[TBL] [Abstract][Full Text] [Related]
22. Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer.
Cho EK; Park JY; Lee KH; Song HS; Min YJ; Kim YH; Kang JH
Cancer Chemother Pharmacol; 2014 Jan; 73(1):9-16. PubMed ID: 24337589
[TBL] [Abstract][Full Text] [Related]
23. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
[TBL] [Abstract][Full Text] [Related]
24. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Takimoto CH; Remick SC; Sharma S; Mani S; Ramanathan RK; Doroshow J; Hamilton A; Mulkerin D; Graham M; Lockwood GF; Ivy P; Egorin M; Schuler B; Greenslade D; Goetz A; Knight R; Thomas R; Monahan BP; Dahut W; Grem JL;
J Clin Oncol; 2003 Jul; 21(14):2664-72. PubMed ID: 12860942
[TBL] [Abstract][Full Text] [Related]
25. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Leal TB; Remick SC; Takimoto CH; Ramanathan RK; Davies A; Egorin MJ; Hamilton A; LoRusso PA; Shibata S; Lenz HJ; Mier J; Sarantopoulos J; Mani S; Wright JJ; Ivy SP; Neuwirth R; von Moltke L; Venkatakrishnan K; Mulkerin D
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1439-47. PubMed ID: 21479634
[TBL] [Abstract][Full Text] [Related]
26. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.
Gietema JA; de Vries EG; Sleijfer DT; Willemse PH; Guchelaar HJ; Uges DR; Aulenbacher P; Voegeli R; Mulder NH
Br J Cancer; 1993 Feb; 67(2):396-401. PubMed ID: 8431374
[TBL] [Abstract][Full Text] [Related]
27. Phase I and pharmacologic study of topotecan in patients with impaired renal function.
O'Reilly S; Rowinsky EK; Slichenmyer W; Donehower RC; Forastiere AA; Ettinger DS; Chen TL; Sartorius S; Grochow LB
J Clin Oncol; 1996 Dec; 14(12):3062-73. PubMed ID: 8955651
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function.
Massari C; Brienza S; Rotarski M; Gastiaburu J; Misset JL; Cupissol D; Alafaci E; Dutertre-Catella H; Bastian G
Cancer Chemother Pharmacol; 2000; 45(2):157-64. PubMed ID: 10663631
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.
Devriese LA; Witteveen PE; Mergui-Roelvink M; Smith DA; Lewis LD; Mendelson DS; Bang YJ; Chung HC; Dar MM; Huitema AD; Beijnen JH; Voest EE; Schellens JH
Br J Clin Pharmacol; 2015 Aug; 80(2):253-66. PubMed ID: 25677219
[TBL] [Abstract][Full Text] [Related]
30. Relationship of systemic exposure to unbound docetaxel and neutropenia.
Baker SD; Li J; ten Tije AJ; Figg WD; Graveland W; Verweij J; Sparreboom A
Clin Pharmacol Ther; 2005 Jan; 77(1):43-53. PubMed ID: 15637530
[TBL] [Abstract][Full Text] [Related]
31. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.
Cass LM; Efthymiopoulos C; Marsh J; Bye A
Clin Pharmacokinet; 1999; 36 Suppl 1():13-9. PubMed ID: 10429836
[TBL] [Abstract][Full Text] [Related]
32. The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist, in varying degrees of renal impairment.
Dhaun N; Melville V; Kramer W; Stavros F; Coyne T; Swan S; Goddard J; Webb DJ
Br J Clin Pharmacol; 2007 Dec; 64(6):733-7. PubMed ID: 17635499
[TBL] [Abstract][Full Text] [Related]
33. A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment.
Laille E; Goel S; Mita AC; Gabrail NY; Kelly K; Liu L; Songer S; Beach CL
Pharmacotherapy; 2014 May; 34(5):440-51. PubMed ID: 24877181
[TBL] [Abstract][Full Text] [Related]
34. Extension of the Calvert formula to patients with severe renal insufficiency.
Oguri T; Shimokata T; Ito I; Yasuda Y; Sassa N; Nishiyama M; Hamada A; Hasegawa Y; Ando Y
Cancer Chemother Pharmacol; 2015 Jul; 76(1):53-9. PubMed ID: 25957958
[TBL] [Abstract][Full Text] [Related]
35. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
Sobue S; Tan K; Layton G; Leclerc V; Weil A
Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of sparfloxacin in patients with renal impairment.
Dorr MB; Johnson RD; Jensen B; Magner D; Marbury T; Talbot GH
Clin Ther; 1999 Jul; 21(7):1202-15. PubMed ID: 10463518
[TBL] [Abstract][Full Text] [Related]
37. Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.
de Jonge MJ; Glimelius B; Verweij J; Van Groeningen C; Bonneterre J; de Vries EG; Culine S; Young J; Smith R; Droz J
Anticancer Drugs; 2002 Jul; 13(6):645-53. PubMed ID: 12172511
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
[TBL] [Abstract][Full Text] [Related]
39. Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment.
Merdjan H; Tarral A; Das S; Li J
J Clin Pharmacol; 2017 Feb; 57(2):211-218. PubMed ID: 27402250
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and Tolerability of Lorcaserin in Special Populations: Elderly Patients and Patients with Renal or Hepatic Impairment.
Christopher RJ; Morgan ME; Tang Y; Anderson C; Sanchez M; Shanahan W
Clin Ther; 2017 Apr; 39(4):837-848.e7. PubMed ID: 28365033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
